Novartis

Novartis NVS Stock

$155.21   -2.463390%
Add to favorites
Exchange
Market Cap
$293.13B
LOW - HIGH [24H]
$154.81 - $157.98
VOLUME [24H]
$2.75M
P/E Ratio
29.62
Earnings per share
$5.24
ISIN
US66987V1098
Price   Prediction

Novartis Price Chart

Sorry, that's all we've gotfor now...

Novartis (NVS) stock price today is 155.21 USD on NYSE (-2.46% on the day). Updated .

Novartis NVS Financial and Trading Overview

Novartis stock price 155.21 USD
Previous Close 160.2 USD
Open 158.46 USD
Bid 0 USD x 10000
Ask 0 USD x 10000
Day's Range 158.38 - 160.03 USD
52 Week Range 123.24 - 170.46 USD
Volume 1.46M USD
Avg. Volume 2.13M USD
Market Cap 300.54B USD
Beta (5Y Monthly) 0.453
PE Ratio (TTM) 30.368322
EPS (TTM) 5.24 USD
Forward Dividend & Yield 4.74 (2.97%)
Ex-Dividend Date March 11, 2026
1y Target Est 157.1 USD

NVS Valuation Measures

Enterprise Value 340.31B USD
Trailing P/E 30.368322
Forward P/E 16.020966
PEG Ratio (5 yr expected) 3.81
Price/Sales (ttm) 5.2391167
Price/Book (mrq) 8.072748
Enterprise Value/Revenue 5.932
Enterprise Value/EBITDA 14.141

Trading Information

Novartis Stock Price History

Beta (5Y Monthly) 0.453
52-Week Change 25.14%
S&P500 52-Week Change 12.07%
52 Week High 170.46 USD
52 Week Low 123.24 USD
50-Day Moving Average 149.14 USD
200-Day Moving Average 152.63 USD

NVS Share Statistics

Avg. Volume (3 month) 2.13M USD
Avg. Daily Volume (10-Days) 1.93M USD
Shares Outstanding 1.89B
Float 1.84B
Short Ratio 2.14
% Held by Insiders 0.012%
% Held by Institutions 7.22%
Shares Short 4.52M
Short % of Float 0.23%
Short % of Shares Outstanding 0.23%

Dividends & Splits

Trailing Annual Dividend Rate 4.666
Trailing Annual Dividend Yield 2.91%
5 Year Average Dividend Yield 346.00%
Payout Ratio 0.90459996
Last Split Factor 1116:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 17.48%
Operating Margin (ttm) 33.98%
Gross Margin 75.20%
EBITDA Margin 41.95%

Management Effectiveness

Return on Assets (ttm) 10.85%
Return on Equity (ttm) 24.32%

Income Statement

Revenue (ttm) 57.36B USD
Revenue Per Share (ttm) 30.1 USD
Quarterly Revenue Growth (yoy) 4.70%
Gross Profit (ttm) 43.14B USD
EBITDA 24.07B USD
Net Income Avi to Common (ttm) 10.03B USD
Diluted EPS (ttm) 5.24
Quarterly Earnings Growth (yoy) -69.39%

Balance Sheet

Total Cash (mrq) 8.87B USD
Total Cash Per Share (mrq) 4.7 USD
Total Debt (mrq) 48.31B USD
Total Debt/Equity (mrq) 128.61 USD
Current Ratio (mrq) 0.884
Book Value Per Share (mrq) 19.712

Cash Flow Statement

Operating Cash Flow (ttm) 17.33B USD
Levered Free Cash Flow (ttm) 11.27B USD

Profile of Novartis

Country United States
State N/A
City Basel
Address Lichtstrasse 35
ZIP 4056
Phone 41 61 324 11 11
Website https://www.novartis.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 75267

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Q&A For Novartis Stock

What is a current NVS stock price?

Novartis NVS stock price today per share is 155.21 USD.

How to purchase Novartis stock?

You can buy NVS shares on the NYSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Novartis?

The stock symbol or ticker of Novartis is NVS.

Which industry does the Novartis company belong to?

The Novartis industry is Drug Manufacturers - General.

How many shares does Novartis have in circulation?

The max supply of Novartis shares is 1.89B.

What is Novartis Price to Earnings Ratio (PE Ratio)?

Novartis PE Ratio is 29.62023200 now.

What was Novartis earnings per share over the trailing 12 months (TTM)?

Novartis EPS is 5.24 USD over the trailing 12 months.

Which sector does the Novartis company belong to?

The Novartis sector is Healthcare.

Novartis NVS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech OMX CRD Global Sustainab QCRD US 1595.1 USD —
0
— — — — — — — — —
us NYSE Arca Pharmaceutical Index DRG US 1343.1 USD —
-2.2
— — 1340.56 USD — 1373.02 USD — — — —
us NYSE Composite Index NYA US 23559.61 USD —
-1.06
— — 23530.84 USD — 23742.73 USD — — — —
$2.18T
Total marketcap
$71.97B
Total volume
BTC 58.09%   •   ETH 9.98%
Dominance
Select currency